Achilles Therapeutics plc (ACHL)
Achilles Therapeutics plc operates in the Biotechnology industry of the Healthcare sector, headquartered in London, GB. The stock last traded at $1.48, up 0.68% on the session, giving a market capitalisation of $60.8M. On trailing twelve-month figures it carries a trailing P/E of -0.85, a net margin of 0.0%. Its beta of 1.25 implies it has historically moved more than the broad market.
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
Achilles Therapeutics plc is most often compared with the following Healthcare names: